NOVARTIS joins the Rare Disease Action Forum as member

    20 Feb, 2020

    In February 2020 Novartis joined the Rare Disease Action Forum (RDAF) as member. With its members coming from industry, patient organizations, Healthcare Professionals and research organizations, the RDAF acts as multi-stakeholder platform in the field of rare diseases. With its increased membership the RDAF reinforces its contribution to improve access to diagnosis, treatment and patient care for patients with rare diseases in Switzerland.

    Continue reading

    The RDAF publishes its newsletter

    The newsletter, which is published twice a year, gives an overview of all the Rare Disease Action Forum (RDAF) activities during the past half year to raise awareness about rare diseases in Switzerland and improve patient’s access to diagnosis, treatment and care....

    RDAF 2022 General Assembly Meeting

    On 21 March 2022, the Rare Disease Action Forum (RDAF) held its annual General Assembly meeting. An overview of the RDAF’s activities in 2021 and an outlook for 2022 were presented. The RDAF President welcomed the new members and underlined that the collaborative...